Responses
Late-breaking abstracts
Clinical trials in-progress
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
